Skip to main content
Publications
Weibel D, Sturkenboom M, Eijkemans R, van den Bor R, Elbers R, Plana E, Garcia de Albeniz X, Weinrib R, Yefimenko N, Bianchini E, Stona L, Poblador-Plou B, Swart-Polinder K, Bartolini C, Hyeraci RG, Roy D, Lupattelli A, Villalobos F, Barbieri E, Garg RK, Rubino H, De Luise C, Arana A. VAC4EU active safety surveillance study of the BNT162b2 COVID-19 vaccine in five European countries: study design and first results. Presentation to be given at the 2022 ICPE Conference; August 2022. Copenhagen, Denmark.
Saigi-Morgui N, Rebordosa C, Plana E, Rubino A, Aguado J, Martinez D, Lei A, Daoud SZ, McMahon P, Perez-Gutthann S, Rivero-Ferrer E. Acute myocardial infarction, stroke, and MACE in COPD patients treated withaclidinium and other inhaled bronchodilators. Poster to be given at the 2022 ICPE Conference; August 2022. Copenhagen, Denmark.
Rivero-Ferrer E, Olesen M, Plana E, Aguado J, Saigi-Morgui N, Rubino A, Daoud SZ, Lei A, Perez-Gutthann S, Schink S, Kristiansen NS, Hallas J, Pottegard A, Rebordosa C. Characteristics of new users of aclidinium bromide, aclidinium/formoterol, and other COPD medications in the United Kingdom, Denmark, and Germany. Clin Drug Invest. 2022 Apr;42(4):319-31. doi: 10.1007/s40261-022-01120-2
Forns J, Dudukina E, Hagg D, Szentkuti EP, Gembert K, Plana E, Gilsenan A, Horvath-Puho E, Reutfors J, Rebordosa C. Cohort study of the incidence of major cardiovascular events in new adult users of lisdexamfetamine and remote adult users of other attention-deficit/hyperactivity disorder treatments. Poster presented at the 2021 8th World Congress on ADHD Virtual Event; May 6, 2021.
Rebordosa C, Rubino A, Witzleb AJ, Olesen M, Plana E, Aguado J, Saigi N, Daoud SZ, Lei A, Perez-Gutthann S, Schink T, Kristiansen NS, Pottegard A, Rivero-Ferrer E. Characteristics of new users of aclidinium, aclidinium/formoterol, and other COPD medications in three European countries. Poster presented at the 2020 Virtual ERS International Congress; October 2020. [abstract] Eur Respir J. 2020 Oct 28; 56(Suppl 64):2071. doi: 10.1183/13993003.congress-2020.2072
Rivero-Ferrer E, Witzleb AJ, Olesen M, Plana E, Aguado J, Saigi-Morgui N, Rubino A, Daoud SZ, Lei A, Perez-Gutthann S, Schink T, Kristiansen NS, Pottegard A, Rebordosa C. Are aclidinium and aclidinium/formoterol used according to their approved indication in Europe? Results of a multicountry drug utilization postauthorization safety study. Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.
Gilsenan A, Fortuny J, Cainzos-Achirica M, Cantero OF, Flynn RWV, Garcia-Rodriguez L, Harding A, Kollhorst B, Karlsson P, Linner L, MacDonald TM, Odsbu E, Plana E, Ruigomez A, Schink T, Ziemiecki R, Andrews EB. Cardiovascular safety of prucalopride in patients with chronic constipation: a multinational population-based cohort study. Drug Saf. 2019 Oct;42(10):1179-90. doi: 10.1007/s40264-019-00835-0
Fortuny J, Gilsenan A, Cainzos-Achirica M, Cantero OF, Flynn RWV, Garcia-Rodriguez L, Kollhorst B, Karlsson P, Linner L, MacDonald TM, Plana E, Ruigomez A, Schink T, Ziemiecki R, Andrews EB. Study design and cohort comparability in a study of major cardiovascular events in new users of prucalopride versus polyethylene glycol 3350. Drug Saf. 2019 Oct;47(10):1167-77. doi: 10.1007/s40264-019-00836-z
Gilsenan A, Fortuny J, Cainzos-Achirica M, Cantero OF, Flynn RW, Garcia-Rodriguez L, Harding A, Kollhorst B, Karlsson P, Linner L, MacDonald TM, Odsbu I, Plana E, Ruigomez A, Schink T, Ziemiecki R, Andrews EB. Cardiovascular safety of prucalopride for chronic constipation: a multinational population-based cohort study. Presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):33. doi: 10.1002/pds.4864
Plana E, Rivero-Ferrer E, Aguado J, Saigi-Morgui N, Nuevo J, Daoud SZ, Lei A, Perez-Gutthann S, Rebordosa C. Hospitalization for heart failure among patients using aclidinium bromide and other COPD medications: a post-authorisation safety study in the CPRD. Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):1153. doi: 10.1002/pds.4864
Fortuny J, Gilsenan AW, Cainzos-Achirica M, Cantero OF, Flynn RW, Garcia-Rodriguez L, Kollhorst B, Karlsson P, Linner L, MacDonald TM, Plana E, Ruigomez A, Schink T, Ziemiecki R, Andrews EB. Cohort study of the relative incidence of major cardiovascular events among patients initiating prucalopride versus a matched comparator cohort in a multinational study: study design and comparability of cohorts. Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):627. doi: 10.1002/pds.4864
Saigi N, Rebordosa C, Bui C, Aguado J, Plana E, Nuevo J, Daoud SZ, Lei A, Perez-Gutthann S, Rivero-Ferrer E. A validation exercise: identifying hospitalizations for heart failure among patients with COPD in the CPRD. Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):334. doi: 10.1002/pds.4864
Cainzos-Achirica M, Ruigomez A, MacDonald T, Garcia-Rodriguez L, Fortuny J, Flynn RW, Plana E, Ziemiecki R, Andrews EB, Gilsenan A. Validation of major cardiovascular events in a multi-database post-authorization safety study of prucalopride. Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):331. doi: 10.1002/pds.4864
Rebordosa C, Aguado J, Plana E, Thomas S, Frances A, Lei A, Garcia-Gil E, Nuevo J, Perez-Gutthann S, Castellsague J. Use of aclidinium did not increase the risk of death in a noninterventional cohort study in the Clinical Practice Research Datalink (CPRD), United Kingdom. Respir Med. 2019 Jun;152:37-43. doi: 10.1016/j.rmed.2019.04.018
Margulis AV, Fortuny J, Kaye JA, Calingaert B, Reynolds M, Plana E, McQuay LJ, Jan Atsma W, Franks B, de Vogel S, Perez-Gutthann S, Arana A. Proportions of cancer cases in primary care, hospital, and cancer registry data among patients treated for overactive bladder. Letter to editor. Epidemiology. 2019 Mar;30(2):e8-9. doi: 10.1097/EDE.0000000000000953
Margulis AV, Fortuny J, Kaye JA, Calingaert B, Reynolds M, Plana E, McQuy LJ, Atsma WJ, Franks B, de Vogel S, Perez-Gutthann S, Arana A. Value of free-text comments for validating cancer cases using primary-care data in the United Kingdom. Epidemiology. 2018 Sep;29(5):e41-2.
Tormos A, Rebordosa C, Thomas S, Plana E, Rasouliyan L, Pladevall-Vila M, Fazeli-Farsani S, Deruaz-Luyet A, Brodovicz KG, Perez-Gutthann S. Time between laboratory tests and acute liver and kidney injury diagnosis codes in CPRD: are we doing it right? Poster presented at the 34th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2018. Prague, Czech Republic. [abstract] Pharmacoepidemiol Drug Saf. 2018 Aug; 27(S2):452. doi: 10.1002/pds.4629
Margulis AV, D'Onofrio B, Almqvist C, McElrath T, Oberg AS, Plana E, Rothman KJ, Hernandez-Diaz S. Antiepileptic drugs in pregnancy and duration of pregnancy, birth weight, length, and head circumference. Poster presented at the 34th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 25, 2018. Prague, Czech Republic. [abstract] Pharmacoepidemiol Drug Saf. 2018 Aug; 27(S2):234. doi: 10.1002/pds.4629
Cainzos-Achirica M, Rebordosa C, Vela E, Cleries M, Matsushita K, Plana E, Rivero-Ferrer E, Enjuanes C, Jimenez-Marrero S, Garcia-Rodriguez LA, Comin-Colet J, Perez-Gutthann S. Challenges of evaluating chronic heart failure and acute heart failure events in research studies using large health care databases. Am Heart J. 2018 Aug;202:76-83. doi: 10.1016/j.ahj.2018.05.005
Cainzos-Achirica M, Varas-Lorenzo C, Pottegard A, Asmar J, Plana E, Rasmussen L, Bizouard G, Forns J, Hellfritzsch M, Zint K, Perez-Gutthann S, Pladevall-Vila M. Methodological challenges when evaluating potential off-label prescribing of drugs using electronic health care databases: a case study of dabigatran etexilate in Europe. Pharmacoepidemiol Drug Saf. 2018 Jul;27(7):713-23. doi: 10.1002/pds.4416
Gilsenan A, Fortuny J, Plana E, Ruigomez A, Karlsson P, Flynn RWV, Cantero OF, Garcia-Rodriguez L, Linner L, Cainzos-Achirica M, Bartsch J, MacDonald T, Kieler H, Andrews EB. Non-interventional cohort study of the relative incidence of major cardiovascular events among patients initiating prucalopride versus a matched comparator cohort initiating polyethylene glycol 3350 (PEG). Poster presented at the 2018 Digestive Disease Week; June 3, 2018. Washington, DC.
Margulis AV, Fortuny J, Kaye JA, Calingaert B, Reynolds M, Plana E, McQuay LJ, Atsma WJ, Franks B, de Vogel S, Perez-Gutthann S, Arana A. Validation of cancer cases using primary care, cancer registry, and hospitalization data in the UK. Epidemiology. 2018 Mar;29(2):308-13. doi: 10.1097/EDE.0000000000000786
Norback D, Zock JP, Plana E, Heinrich J, Tischer C, Jacobsen R, Sunyer J, Kunzli N, Villani S, Olivieri M, Verlato G, Soon A, Schlunssen V, Gunnbjornsdottir MI, Jarvis D. Building dampness and mould in European homes in relation to climate, building characteristics and socio-economic status: the European Community Respiratory Health Survey ECRHS II. Indoor Air. 2017 Sep;27(5):921-32. doi: 10.1111/ina.12375
Rebordosa C, Castellsague J, Kristiansen N, Pottegard A, Plana E, Aguado J, Garcia-Gil E, Hallas J, Perez-Gutthann S. Severity of COPD in new users of aclidinium bromide and other COPD medications: a population-based study in the United Kingdom and Denmark. Presented at the 33rd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2017. Montreal, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2017 Aug; 26(Suppl 2):45-6. doi: 10.1002/pds
Cainzos-Achirica M, Varas-Lorenzo C, Pottegard A, Asmar J, Plana E, Rasmussen L, Bizouard G, Forns J, Hellfritzsch M, Zint K, Perez-Gutthann S, Pladevall-Vila M. Evaluation of potential off-label prescribing of dabigatran etexilate in France, Denmark, and the United Kingdom and associated methodological challenges. Poster presented at the 33rd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 30, 2017. Montreal, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2017 Aug; 26(Suppl 2):566. doi: 10.1002/pds
Tell-Marti G, Puig-Butille JA, Potrony M, Plana E, Badenas C, Antonell A, Sanchez-Valle R, Molinuevo JL, Lleo A, Alcolea D, Fortea J, Fernandez-Santiago R, Clarimon J, Llado A, Puig S. A common variant in the MC1R gene (p.V92M) is associated with Alzheimer's disease risk. J Alzheimers Dis. 2017 Feb 3;56(3):1065-74. doi: 10.3233/JAD-161113
Afonso A, Schmiedl S, Becker C, Tcherny-Lessenot S, Primatesta P, Plana E, Souverein P, Wang Y, Korevaar JC, Hasford J, Reynolds R, de Groot MC, Schlienger R, Klungel O, Rottenkolber M. A methodological comparison of two European primary care databases and replication in a US claims database: inhaled long-acting beta-2-agonists and the risk of acute myocardial infarction. Eur J Clin Pharmacol. 2016 Sep;72(9):1105-16.
Margulis AV, Varas-Lorenzo C, Bui CL, McQuay LJ, Ziemiecki R, Reynolds M, Rebordosa C, Pladevall-Vila M, Fortuny J, Rivero-Ferrer E, Plana E, Atsma WJ, Appenteng K, Franks B, de Vogel S, D'Silva M, Perez-Gutthann S, Arana A. Validation of cardiovascular events and covariates in CPRD GOLD using questionnaires to general practitioners (GPS). Presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):255-6.
McGrath LJ, Rulgomez A, Plana E, Fortuny J, Garcia-Rodriguez L, Rebordosa C, Varas-Lorenzo C, Ziemiecki R, Gilsenan AW, Andrews E. Characteristics of patients prescribed prucalopride versus an active comparator in England, Wales, and Northern Ireland. Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):634.
Plana E, McGrath LJ, Fortuny J, Ruigomez A, Fernandez-Cantero O, Garcia-Rodriguez LA, Gilsenan AW, Andrews E, Rebordosa C, Ziemiecki R. An algorithm to identify duplicate patients when pooling aggregate data from two primary care databases in the United Kingdom. Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):58-9. doi: 10.1002/pds
